Brief: Hoth Therapeutics Announces Positive Initial Data In Phase 2A Clinical Trial
15/04/2025 14:33
April 15 (Reuters) - Hoth Therapeutics Inc HOTH.O: HOTH THERAPEUTICS ANNOUNCES POSITIVE INITIAL DATA IN PHASE 2A CLINICAL TRIAL HOTH THERAPEUTICS INC - PATIENTS EXPERIENCED A 50% REDUCTION IN PRURITUS SEVERITY, WITH MEAN SCORES DROPPING FROM 1.6 ON DAY 1 TO 0.8 BY DAY 21 HOTH THERAPEUTICS INC - HT-001 WAS WELL TOLERATED, WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS REPORTED Source text: ID:nPn7mLV8ha Further company coverage: HOTH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket One
See all newsBrief: Rocket One Signs AI Chip Development Agreement Targeting Ultra-Low-Power Magnetic Computing
Brief: Rocket One Signs Agreement To Advance Nanomagnetic Ai Chip Technology And Device Prototyping
Brief: Rocket One Signs Patent License Agreement With U.S. Air Force For Technology Designed To Capture And Neutralize Hostile Drones
Brief: Rocket One To Buy 100% Ownership Of Tracer Drone Technologies
Brief: Rocket One And Nasa Reach Agreement To Advance Space Ai Technology